| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
4,629 |
4,224 |
$1.52M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,223 |
3,933 |
$1.03M |
| 59025 |
Fetal non-stress test |
3,934 |
3,181 |
$478K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
3,936 |
3,350 |
$444K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,335 |
3,317 |
$292K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
3,153 |
2,973 |
$160K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,653 |
2,559 |
$160K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
2,249 |
2,133 |
$130K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,937 |
1,757 |
$113K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
1,905 |
1,671 |
$106K |
| 80053 |
Comprehensive metabolic panel |
9,337 |
8,309 |
$105K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
1,129 |
939 |
$104K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
1,049 |
1,020 |
$94K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
10,988 |
9,764 |
$88K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,581 |
1,342 |
$79K |
| 87653 |
|
1,376 |
1,344 |
$56K |
| 70450 |
Computed tomography, head or brain; without contrast material |
329 |
310 |
$46K |
| 81002 |
|
8,867 |
6,070 |
$37K |
| 71045 |
Radiologic examination, chest; single view |
1,411 |
1,290 |
$36K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
656 |
644 |
$28K |
| 86850 |
|
1,261 |
1,147 |
$23K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
253 |
247 |
$18K |
| 87486 |
|
418 |
397 |
$18K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
421 |
397 |
$17K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
142 |
135 |
$15K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
101 |
98 |
$14K |
| 81001 |
|
4,177 |
3,611 |
$13K |
| 84484 |
|
1,287 |
695 |
$11K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
153 |
94 |
$9K |
| 86780 |
|
615 |
594 |
$9K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,132 |
967 |
$9K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
429 |
404 |
$8K |
| 82077 |
|
476 |
444 |
$8K |
| 86701 |
|
722 |
694 |
$7K |
| 56820 |
|
82 |
77 |
$6K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
364 |
336 |
$6K |
| 83615 |
|
723 |
580 |
$5K |
| 82570 |
|
731 |
612 |
$5K |
| 80320 |
|
351 |
322 |
$5K |
| 86703 |
|
226 |
205 |
$4K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
12 |
12 |
$4K |
| 83880 |
|
147 |
134 |
$4K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
1,318 |
1,053 |
$4K |
| 86901 |
|
1,296 |
1,172 |
$4K |
| 86900 |
|
1,296 |
1,172 |
$4K |
| 86803 |
|
221 |
211 |
$4K |
| 84156 |
|
734 |
613 |
$3K |
| 87899 |
|
164 |
146 |
$3K |
| U0004 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r |
31 |
28 |
$3K |
| 76818 |
|
19 |
16 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
95 |
91 |
$2K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
79 |
72 |
$2K |
| 84112 |
|
26 |
25 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
78 |
68 |
$2K |
| 86762 |
|
143 |
101 |
$2K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
13 |
12 |
$2K |
| 86592 |
|
344 |
309 |
$2K |
| 83690 |
|
267 |
256 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
116 |
114 |
$2K |
| 85027 |
|
253 |
220 |
$2K |
| 81003 |
|
678 |
612 |
$2K |
| 85610 |
|
534 |
498 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
43 |
39 |
$1K |
| 84702 |
|
114 |
94 |
$1K |
| 59430 |
|
44 |
38 |
$1K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
83 |
80 |
$1K |
| 87340 |
|
104 |
98 |
$1K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
33 |
25 |
$1K |
| 82550 |
|
120 |
110 |
$938.94 |
| 36415 |
Collection of venous blood by venipuncture |
13,245 |
10,859 |
$874.01 |
| 81025 |
|
85 |
78 |
$725.05 |
| G0378 |
Hospital observation service, per hour |
29 |
12 |
$640.33 |
| 90674 |
|
44 |
44 |
$635.42 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
29 |
15 |
$586.04 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
448 |
355 |
$537.10 |
| 80048 |
Basic metabolic panel (calcium, ionized) |
104 |
83 |
$508.52 |
| 87088 |
|
26 |
24 |
$463.82 |
| 85730 |
|
116 |
109 |
$405.92 |
| 87210 |
|
67 |
66 |
$392.67 |
| 90661 |
|
27 |
27 |
$341.54 |
| 84703 |
|
16 |
14 |
$256.47 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
15 |
15 |
$242.12 |
| 83020 |
|
13 |
13 |
$185.74 |
| 90656 |
|
13 |
13 |
$94.15 |
| 87147 |
|
18 |
17 |
$89.56 |
| 83605 |
|
12 |
12 |
$82.57 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
338 |
281 |
$82.24 |
| 87081 |
|
13 |
13 |
$81.49 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
77 |
54 |
$41.75 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
52 |
37 |
$24.42 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
56 |
52 |
$20.70 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
62 |
39 |
$6.41 |
| J2704 |
Injection, propofol, 10 mg |
381 |
258 |
$0.00 |
| A9270 |
Non-covered item or service |
695 |
238 |
$0.00 |
| 82962 |
|
215 |
123 |
$0.00 |